Iqvia initiated with an Overweight at Stephens

Stephens initiated coverage of Iqvia (IQV) with an Overweight rating and $250 price target The firm says the company has “fulfilled the promise” of combining a leading contract research organization and the largest life science data repository to connect intelligence that advances healthcare. The analyst views the company’s Q3 reset, as well as the recent outline of “reasonably conservative” fiscal 2025 and long-term growth frameworks, as creating an attractive setup “for a well-run industry bellwether.”